Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:264360.
doi: 10.1155/2010/264360. Epub 2010 May 20.

Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma

Anna Minchom  1 , Robin L Jones, Cyril Fisher, Omar Al-Muderis, Sue Ashley, Michelle Scurr, Vasilios Karavasilis, Ian R Judson
Affiliations

Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma

Anna Minchom et al. Sarcoma. 2010.

Abstract

Background. This paper aimed to assess the utility of second-line chemotherapy in patients with advanced soft-tissue sarcoma. Materials and Methods. A retrospective search of a prospectively maintained database identified patients treated between 1991 and 2005. Patients with gastrointestinal stromal tumours, small round cell tumours, and Ewing's sarcoma were excluded. Response was assessed using WHO and RECIST. Patients who achieved stable disease for 6 months or more were classified as having disease control. Results. Three hundred and seventy-nine patients received second-line chemotherapy. Eighty-six (22.7%) achieved disease control. Median duration of response was 11 months (95% CI: 9-13). On multivariate analysis, pathological subtype, absence of lung metastases, and the use of combination chemotherapy were independent predictors of disease control. Twenty-eight (16.1%) patients who failed to respond to first-line therapy achieved disease control. Eight (2.1%) patients had sufficient downstaging to enable complete surgical resection. Progression-free survival was 23% at 6 months. Median overall survival was 8 months (95% CI: 7-10 months). On multivariate analysis, synovial histology and absence of lung metastases were associated with improved survival. Conclusion. Second-line chemotherapy can provide clinical benefit in over 20% of soft-tissue sarcoma patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Duration of disease control.
Figure 2
Figure 2
Overall survival.
See this image and copyright information in PMC

References

    1. Singer S, Demetri GD, Baldini EH, Fletcher CDM. Management of soft-tissue sarcomas: an overview and update. The Lancet Oncology. 2000;1(2):75–85. - PubMed
    1. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. New England Journal of Medicine. 2005;353(7):701–711. - PubMed
    1. Blay J-Y, van Glabbeke M, Verweij J, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. European Journal of Cancer. 2003;39(1):64–69. - PubMed
    1. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist. 2005;10(10):833–841. - PubMed
    1. Hartmann JT, Patel S. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs. 2005;65(2):167–178. - PubMed

LinkOut - more resources